The stock of Nivalis Therapeutics Inc (NASDAQ:NVLS) reached all time low today, Nov, 29 and still has $2.62 target or 9.00% below today’s $2.88 share price. This indicates more downside for the $44.55 million company. This technical setup was reported by Barchart.com. If the $2.62 PT is reached, the company will be worth $4.01 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 1.64 million shares traded hands or 2234.59% up from the average. Nivalis Therapeutics Inc (NASDAQ:NVLS) has risen 39.51% since April 26, 2016 and is uptrending. It has outperformed by 34.25% the S&P500.
Analysts await Nivalis Therapeutics Inc (NASDAQ:NVLS) to report earnings on March, 6. They expect $-0.58 EPS, down 38.10% or $0.16 from last year’s $-0.42 per share. After $-0.48 actual EPS reported by Nivalis Therapeutics Inc for the previous quarter, Wall Street now forecasts 20.83% negative EPS growth.
According to Zacks Investment Research, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.”
More news for Nivalis Therapeutics Inc (NASDAQ:NVLS) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on July 13, 2009. Globenewswire.com‘s article titled: “Nivalis Therapeutics Announces Pricing of Its Initial Public Offering” and published on June 17, 2015 is yet another important article.
NVLS Company Profile
Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is a clinical-stage pharmaceutical company. The Firm discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). The Firm focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. The Firm operates through discovering and development of potential drugs segment. The Company’s activities are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. GSNOR inhibitor portfolio includes other compounds with differing chemical structures and properties suitable for oral, inhaled, injectable and topical administration. The Company’s drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.